1. Home
  2. EIC vs ALT Comparison

EIC vs ALT Comparison

Compare EIC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIC
  • ALT
  • Stock Information
  • Founded
  • EIC N/A
  • ALT 1997
  • Country
  • EIC United States
  • ALT United States
  • Employees
  • EIC N/A
  • ALT N/A
  • Industry
  • EIC Finance/Investors Services
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • EIC Finance
  • ALT Health Care
  • Exchange
  • EIC Nasdaq
  • ALT Nasdaq
  • Market Cap
  • EIC 334.1M
  • ALT 348.6M
  • IPO Year
  • EIC 2019
  • ALT N/A
  • Fundamental
  • Price
  • EIC $12.01
  • ALT $4.22
  • Analyst Decision
  • EIC
  • ALT Strong Buy
  • Analyst Count
  • EIC 0
  • ALT 7
  • Target Price
  • EIC N/A
  • ALT $16.33
  • AVG Volume (30 Days)
  • EIC 140.6K
  • ALT 2.9M
  • Earning Date
  • EIC 11-13-2025
  • ALT 11-06-2025
  • Dividend Yield
  • EIC 12.98%
  • ALT N/A
  • EPS Growth
  • EIC N/A
  • ALT N/A
  • EPS
  • EIC 0.70
  • ALT N/A
  • Revenue
  • EIC $55,581,156.00
  • ALT $20,000.00
  • Revenue This Year
  • EIC $37.84
  • ALT N/A
  • Revenue Next Year
  • EIC $23.33
  • ALT N/A
  • P/E Ratio
  • EIC $17.27
  • ALT N/A
  • Revenue Growth
  • EIC 56.39
  • ALT N/A
  • 52 Week Low
  • EIC $11.96
  • ALT $2.90
  • 52 Week High
  • EIC $16.39
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • EIC 32.80
  • ALT 59.05
  • Support Level
  • EIC $12.22
  • ALT $3.73
  • Resistance Level
  • EIC $12.98
  • ALT $4.36
  • Average True Range (ATR)
  • EIC 0.19
  • ALT 0.21
  • MACD
  • EIC -0.04
  • ALT 0.03
  • Stochastic Oscillator
  • EIC 6.86
  • ALT 77.79

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: